Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (946)	10/5/2009 4:48:10 PM
From: nigel bates	Respond to of 1022

GHENT, Belgium, 5 October 2009 - Ablynx [Euronext Brussels: ABLX], announced today that it has received an undisclosed milestone payment from Novartis for an exclusive research license in one of the programmes that is a component of their ongoing Research and Development alliance. Novartis and Ablynx are collaborating to discover and develop therapeutic Nanobodies® against targets that are difficult to address with conventional antibodies and their fragments. The alliance was entered into in December 2005, and extended in 2007 and again in December 2008 for a further year. Under the terms of this ongoing agreement, Ablynx receives upfront fees, license fees and funding for research and development. In addition, Ablynx will be eligible for milestone payments and royalties upon commercialisation. Novartis has exclusive rights to develop and commercialise the Nanobody® products resulting from the collaboration. Financial terms are not disclosed. Edwin Moses, CEO and Chairman of Ablynx, commented: “We are delighted that a second Nanobody® programme from our collaboration with Novartis is advancing to the next stage and we look forward to seeing these two programmes progressing towards development.” GHENT, Belgium, 1 October 2009 - Ablynx [Euronext Brussels: ABLX], today announced that it will receive milestone payments totalling €3 million from Boehringer Ingelheim triggered as part of its strategic alliance for the development and commercialisation of Nanobodies®. This is the second time Ablynx receives milestone payments from Boehringer Ingelheim since the initiation of the strategic alliance between the companies. Ablynx and Boehringer Ingelheim entered into an agreement in September 2007 to collaborate on the discovery, development and commercialisation of up to 10 different Nanobody® therapeutics across a range of multiple therapeutic areas including for example immunology, oncology and respiratory diseases. The agreement would allow potential milestone payments of up to €125 million for each Nanobody® developed as well as undisclosed royalties to Ablynx. Boehringer Ingelheim is exclusively responsible for the development, manufacture and commercialisation of any products resulting from the collaboration. Ablynx retains certain co-promotion rights in Europe.